http://venturebeat.com/2007/07/30/quark-pharma-withdraws-its-long-shot-ipo/ News About Tech, Money and Innovation Tue, 24 Nov 2009 05:47:06 +0000 http://wordpress.org/?v=2.8.5 hourly 1 http://venturebeat.com/2007/07/30/quark-pharma-withdraws-its-long-shot-ipo/comment-page-1/#comment-757682 VentureBeat » RNA-drug developer Quark aims for $30M after failed IPO Mon, 28 Jan 2008 22:35:50 +0000 http://venturebeat.com/2007/07/30/quark-pharma-withdraws-its-long-shot-ipo/#comment-757682 [...] Fremont, Calif.-based Quark Pharmaceuticals, a biotech developing drugs based on a new technology called RNA interference, hopes to raise $30 million in an eighth funding round, VentureWire reports. Last year, Quark sought $80.5 million in an ultimately abortive IPO. [...] [...] Fremont, Calif.-based Quark Pharmaceuticals, a biotech developing drugs based on a new technology called RNA interference, hopes to raise $30 million in an eighth funding round, VentureWire reports. Last year, Quark sought $80.5 million in an ultimately abortive IPO. [...]

]]> http://venturebeat.com/2007/07/30/quark-pharma-withdraws-its-long-shot-ipo/comment-page-1/#comment-757696 VentureBeat » RNA-drug developer Quark aims for $30M after failed IPO Mon, 28 Jan 2008 22:35:50 +0000 http://venturebeat.com/2007/07/30/quark-pharma-withdraws-its-long-shot-ipo/#comment-757696 [...] Fremont, Calif.-based Quark Pharmaceuticals, a biotech developing drugs based on a new technology called RNA interference, hopes to raise $30 million in an eighth funding round, VentureWire reports. Last year, Quark sought $80.5 million in an ultimately abortive IPO. [...] [...] Fremont, Calif.-based Quark Pharmaceuticals, a biotech developing drugs based on a new technology called RNA interference, hopes to raise $30 million in an eighth funding round, VentureWire reports. Last year, Quark sought $80.5 million in an ultimately abortive IPO. [...]

]]>